Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
SciScore for 10.1101/2020.05.29.20116889: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Blood collection and processing: This observational study was conducted according to the Declaration of Helsinki, in accordance with good clinical practice guidelines, and approved by the Columbia University Institutional Review Board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Pathway analyses were performed with the DAVID software and Ingenuity Pathway Analysis. DAVIDsuggested: (DAVID, RRID:SCR_001881)Ingenuity Pathway Analysissuggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)Graphs and statistical analyses were prepared … SciScore for 10.1101/2020.05.29.20116889: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Blood collection and processing: This observational study was conducted according to the Declaration of Helsinki, in accordance with good clinical practice guidelines, and approved by the Columbia University Institutional Review Board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Pathway analyses were performed with the DAVID software and Ingenuity Pathway Analysis. DAVIDsuggested: (DAVID, RRID:SCR_001881)Ingenuity Pathway Analysissuggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)Graphs and statistical analyses were prepared with GraphPad Prism 8.0 (GraphPad Software, Inc, La Jolla, CA), GENE E (Broad Institute, Cambridge, MA, USA), and MetaboAnalyst 4.0.28 GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)MetaboAnalystsuggested: (MetaboAnalyst, RRID:SCR_015539)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Nonetheless, there are several limitations that affect the interpretation of the results of the present study. First, the analyses presented herein were performed on residual samples obtained for routine clinical laboratory testing. Serum samples were tested here, which clearly impacts any conclusion related to coagulation cascades. In this view, it is worthwhile to note that any conclusion on coagulation phenotype here drawn based on the measurement of protein levels, not direct determination of enzymatic activity. Although these samples were refrigerated and stored for < 24 hours before initial preparation for analysis, future studies on freshly collected samples will determine whether bias was introduced by these sample collection procedures. In addition, the COVID-19 patients studied herein were mostly male (75%) and older (median age 56), as compared to the controls (62% female, median age 33). Although these sex and age-related biases are consistent with what is observed in clinical cohorts, especially with respect to the most severely ill patients, the relatively limited number of younger, female COVID-19 patients studied here prevented any post-hoc analysis based on age and sex as biological variables; nonetheless, samples are now being prospectively collected to perform these additional studies in newly enrolled cohorts. Moreover, all the COVID-19 patients in this study were inpatients and, as such, they were significantly ill. Future studies will investigate whether...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04292899 Completed Study to Evaluate the Safety and Antiviral Activity of Remde… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
